Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

Exclusion Criteria

• •Prior therapy with an anti-CSF1R antibody
• •Prior therapy with PLX3397 unless discontinued for intolerance (i.e., non-progression on prior kinase inhibitor)
• •Liver function tests (including ALT, AST, and total bilirubin), outside of the range of local laboratory normal at Screening
• •Inadequate organ or bone marrow function
• •History of congestive heart failure or myocardial infarction \<1 year prior to first study dose administration
• •Significant abnormalities on ECG at Screening
• •Contraindications to MRI and use of intravenous gadolinium-based contrast agents
• •Creatine Kinase ≥ 1.5x the upper limit of normal
• •Positive test for latent TB at Screening (Quantiferon test)
• •Active known or suspected autoimmune disease